3-(2-Methoxypyrimidin-5-yl)-N-(oxan-4-yl)imidazo[1,2-b]pyridazin-6-amine

Catalog No. :
ACCPEO949
CAS No. :
1012345-09-3
Molecular Formula :
C16H18N6O2
Molecular Weight :
326.36

IUPAC Name:3-(2-methoxypyrimidin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)imidazo[1,2-b]pyridazin-6-amine

3-(2-Methoxypyrimidin-5-yl)-N-(oxan-4-yl)imidazo[1,2-b]pyridazin-6-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$656.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(2-Methoxypyrimidin-5-yl)-N-(oxan-4-yl)imidazo[1,2-b]pyridazin-6-amine
IUPAC Name3-(2-methoxypyrimidin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)imidazo[1,2-b]pyridazin-6-amine
MDL No.MFCD26392238
Molecular FormulaC16H18N6O2
Molecular Weight326.36
SMILESCOC1=NC=C(C2=CN=C3C=CC(NC4CCOCC4)=NN32)C=N1
InChI KeyVRWRCLFBELGLGR-UHFFFAOYSA-N
SynonymImidazo[1,2-b]pyridazin-6-amine, 3-(2-methoxy-5-pyrimidinyl)-N-(tetrahydro-2H-pyran-4-yl)-
CAS No.1012345-09-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACCPEO949 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACCPEH789 route compound structure diagram
    ACCPEH789628692-15-9 In Stock
  4. Then
  5. ACCPEO949 route product structure diagram
    ACCPEO9491012345-09-3
Inquiry

2. ACCPEO949 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCPEH789 route compound structure diagram
    ACCPEH789628692-15-9 In Stock
  2. Plus
  3. ACUBLQ872 route compound structure diagram
    ACUBLQ872923595-49-7 In Stock
  4. Then
  5. ACCPEO949 route product structure diagram
    ACCPEO9491012345-09-3
Inquiry

Comments (0)